Backbone Cyclization
Enhances structural stability, affinity and selectivity
Starget designs Smart Targeted Radioligands (STRs)—AI-optimized molecules that bind to tumor-specific targets and deliver cytotoxic radiation. These radioligands exploit biological differences between tumor and normal tissue to maximize treatment precision.
By leveraging peptide dynamics and AI, we optimize affinity, chelation stability, and biodistribution—key properties for effective and tolerable cancer treatment.
Targeted radioligands are drugs. Like any anti-cancer drugs, they must be efficacious, but most importantly, they must be tolerable to the patient i.e., therapeutic window. The drug must do it precisely, consistently, and tolerably. Therefore, developing STRs is a multidimensional challenge comprising multiple interfaces, including medicinal chemistry, nuclear oncology, and radiopharmaceutical sciences.
Effective and precise STRs rely on the design and delivery of radioactive molecular entities with drug-like properties to enable overcoming the challenges such as:
Our core proprietary platform technology integrates in silico AI with peptide backbone dynamics to engineer the 2D and 3D structural properties of peptide pharmacophores. This AI-powered molecular engine enables the rapid generation of multidimensional molecular diversity—focused on selected peptide scaffolds—to accelerate the discovery of Smart Targeted Radioligands (STRs) with optimized drug-like characteristics.
The Starget platform combines rational peptide design, advanced computational modeling, multiple parallel synthesis, and phage display libraries. Through AI-driven conformational simulation, we apply structural constraints that stabilize peptides in their bioactive form, enhancing on-target affinity, selectivity, and metabolic stability. These candidates are then refined through medicinal chemistry and nuclear oncology workflows to improve pharmacokinetics and tumor uptake.
To further boost radiotherapeutic performance, four modular technologies are applied to each peptide ligand:
Enhances structural stability, affinity and selectivity
Optimizes isotope chelation and backbone assembly
Improves bioavailability and on-target delivery
Refines pharmacokinetics & biodistribution
Starget Pharma is giving cancer patients new hope by harnessing the power of AI and versatility of peptides. By utilizing peptide AI-driven Backbone Dynamics Technology, we transform peptides into successful Smart Targeted Radioligands (STRs) for effective and safe imaging and treatment of cancer.
